As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 13, 2019 at 11:22 AM.

  1. #1 cafead, Sep 13, 2019 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown.

    article source
     
    Quote

Reply to Thread